This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
Stocks · News reference
Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
8-K filing — Turn Therapeutics Inc. (TTRX)
Filed: 2026-09-10 AccNo: 0001213900-26-098584 Size: 213 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits